menu
    • menu
    [{"orgOrder":0,"company":"Liomont","sponsor":"Infinite Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase II","graph3":"Liomont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liomont \/ Infinite Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Liomont \/ Infinite Clinical Research"},{"orgOrder":0,"company":"Liomont","sponsor":"Liomont","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Liomont","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Liomont \/ Liomont","highestDevelopmentStatusID":"11","companyTruncated":"Liomont \/ Liomont"}]

    Find Clinical Drug Pipeline Developments & Deals by Liomont

    Menu

    Liomont

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etoricoxib

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Infinite Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain

                            Details : Etoricoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2023

                            Lead Product(s) : Etoricoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Infinite Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : Materno-Perinatal Hospital of the State of Mexico

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide

                            Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2020

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : Materno-Perinatal Hospital of the State of Mexico

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed

                            Liomont

                            Mexico arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenz...

                            Details : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 09, 2018

                            Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth